CAH
Cardinal Health, Inc.
CAH has slightly lower modeled downside risk, despite its lower overall score.
LLY
Eli Lilly and Company
LLY has the edge over CAH overall, supported by stronger fundamentals and stronger valuation.
CAH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Healthy |
CAH's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CAH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $130 | -53% |
| Forward | 21x | $278 | — |
| Fair | 30x | $231 | -17% |
| Current | 36x | $278 | — |
| Expensive | 44x | $341 | +23% |
Historical ranges are pointers, not guarantees.
CAH has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CAH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Stable | |
| Limited | |
| Moderate |
Analysts expect CAH's earnings to grow, with its revenue and profitability holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over CAH on the outlook, with more favorable revenue and profitability expectations.
CAH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.12 | +70% |
| Q3 2026 | $7.73 | +17% |
| Q2 2026 | $7.23 | +12% |
| Q1 2026 | $6.54 | +2.5% |
| Q4 2025 | $6.95 | +30% |
| Q3 2025 | $6.63 | +30% |
| Q2 2025 | $6.45 | +88% |
| Q1 2025 | $6.38 | +182% |
| Q4 2024 | $5.33 | +109% |
CAH's earnings per share have climbed steadily: $7.73 over the past year, up 17% from the year before, and higher year over year for 15 quarters in a row.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CAH on earnings, with stronger typical year-over-year growth.
CAH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $67.5B | +5.5% |
| Q2 2026 | $63.7B | +5.8% |
| Q1 2026 | $60.9B | +11% |
| Q4 2025 | $65.6B | +19% |
| Q3 2025 | $64B | +22% |
| Q2 2025 | $60.2B | +0.8% |
| Q1 2025 | $54.9B | -0.1% |
| Q4 2024 | $55.3B | -3.8% |
CAH's revenue has grown year over year for six quarters in a row: $67.5B last quarter, up 5.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.1% | +0.1 points |
| Q2 2026 | 1.1% | +0.4 points |
| Q1 2026 | 0.8% | -0.5 points |
| Q4 2025 | 1.1% | +0.1 points |
| Q3 2025 | 1% | -0.1 points |
| Q2 2025 | 0.7% | 0 points |
| Q1 2025 | 1.3% | +0.7 points |
| Q4 2024 | 1% | +0.2 points |
CAH's operating margin was 1.1% last quarter, about level with the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CAH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CAH on profitability, with a higher operating margin.
CAH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.2B | +43% |
| Q2 2026 | $1.4B | +10% |
| Q1 2026 | $1.7B | -40% |
| Q4 2025 | $555M | +$1.1B |
| Q3 2025 | $865M | +$2.6B |
| Q2 2025 | $1.3B | -31% |
| Q1 2025 | $2.8B | +$3B |
| Q4 2024 | -$499M | -146% |
CAH generated $4.9B in free cash flow over the past year, up 10% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CAH on cash flow, with more consistent year-over-year improvement.
CAH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.7% | -4M shares |
| 1 year | -2.5% | -6M shares |
| 3 years | -6.8% | -17M shares |
| 5 years | -19% | -56M shares |
| Available history | -21% | -61M shares |
CAH has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $500M |
| Q2 2026 | $350M |
| Q1 2026 | $250M |
| Q4 2025 | $383M |
| Q3 2025 | $375M |
| Q2 2025 | — |
| Q1 2025 | $375M |
| Q4 2024 | $15M |
CAH spent $1.5B buying back its own shares over the past year, up 94% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CAH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.0x | Very low |
| Q2 2026 | 1.1x | Healthy |
| Q1 2026 | 1.5x | Healthy |
| Q4 2025 | 1.8x | Healthy |
| Q3 2025 | 1.4x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.4x | Healthy |
CAH has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CAH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.8 | Overbought |
| Stochastic | 81.9 | Overbought |
CAH's weekly RSI is 71 (overbought) and its Stochastic is 82 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CAH PE vs Healthcare Sector
| Metric | CAH | Sector median | Relative |
|---|---|---|---|
| PE | 36x | 26x | 39% above |
| PE % | 73 | 29 | 44 pts above |
CAH has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CAH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $248.8 | 12% above |
| 20 week MA | $239.7 | 16% above |
| 50 week MA | $222.0 | 25% above |
| 100 week MA | $185.9 | 50% above |
| 200 week MA | $141.9 | 96% above |
CAH is in an uptrend: it's above all five of its weekly moving averages, and 96% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
CAH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.5 | $53.8 | +4.5% |
| 2021 | $53.8 | $50.8 | -5.7% |
| 2022 | $50.8 | $80.1 | +58% |
| 2023 | $80.1 | $100.8 | +26% |
| 2024 | $100.8 | $119.1 | +18% |
| 2025 | $119.1 | $208.3 | +75% |
| 2026 YTD | $208.3 | $278.1 | +34% |
CAH has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.